Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prevest DenproBOM:543363 +4.23%86 3-Year ROIIC % is 5.99 as of Mar. 2026, which is 65% below its 10-year median of 17.25. GuruFocus rates BOM:543363 with a GF Score™ of 86/100 and a GF Value™ of ₹607.39 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 793 Medical Devices & Instruments companies, Prevest Denpro ranks better than 57.12% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Prevest Denpro's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 5.99%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Prevest Denpro's 3-Year ROIIC % or its related term are showing as below:
BOM:543363's 3-Year ROIIC % is ranked better than 57.12% of 793
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs BOM:543363: 5.99
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Prevest Denpro 3-Year ROIIC % Related Terms
Prevest Denpro 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Prevest Denpro's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543363 vs ISRG, BDX, MDLN: 3-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Prevest Denpro's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prevest Denpro 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prevest Denpro's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Prevest Denpro's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Prevest Denpro (BOM:543363) has a 3-Year ROIIC % of 5.99 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Prevest Denpro and its competitors. This is 65% below median its historical median of 17.25. According to the industry distribution chart, Prevest Denpro ranks #340 out of 793 companies in the Medical Devices & Instruments industry, placing it in the top 42.9%.
Is Prevest Denpro's 3-Year ROIIC % too high?
Prevest Denpro's current 3-Year ROIIC % of 5.99 is 65% below median its 10-year median of 17.25. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.47. Prevest Denpro's value of 5.99 is 307.5% above this industry median. Based on the distribution chart, Prevest Denpro ranks #340 out of 793 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Prevest Denpro has a GF Score™ of 86/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Prevest Denpro's 3-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prevest Denpro ranks #340 out of 793 companies for 3-Year ROIIC %. This puts Prevest Denpro in the upper half of its industry. The industry median 3-Year ROIIC % is 1.47. Prevest Denpro's value of 5.99 is 307.5% above this benchmark. While the company's 10-year median is 17.25 vs. the industry median of 1.47, Prevest Denpro has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 793 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prevest Denpro's current 3-Year ROIIC % of 5.99 is 307.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Prevest Denpro and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prevest Denpro's current 3-Year ROIIC % is 5.99, which is 65% below median its own 10-year median of 17.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prevest Denpro stock overvalued right now?
Based on GuruFocus' analysis, Prevest Denpro (BOM:543363) is currently considered Possible Value Trap. The stock's GF Value™ is ₹607.39, compared to a current price of ₹405.45 — trading 33.2% below its estimated fair value. The current 3-Year ROIIC % is 5.99, which is 65% below median its 10-year median of 17.25 and 307.5% above the Medical Devices & Instruments industry median of 1.47. Prevest Denpro's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Prevest Denpro (BOM:543363), the current 3-Year ROIIC % is 5.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prevest Denpro (BOM:543363) Overvalued in 2026?
Based on GuruFocus' analysis, Prevest Denpro stock appears to be undervalued.
The current stock price of ₹405.45 is trading 33.2% below its estimated GF Value™ of ₹607.39.
GuruFocus considers Prevest Denpro to be Possible Value Trap.
Key valuation signals for BOM:543363:
3-Year ROIIC %: 5.99 (65% below median its 10-year median of 17.25)
GF Value™: ₹607.39 vs. price of ₹405.45 (33.2% below fair value)
Industry Position: 307.5% above the Medical Devices & Instruments median (#340 of 793)
No single metric tells the full story. See the BOM:543363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prevest Denpro Ltd develops, manufactures and markets a comprehensive portfolio of dental materials for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. The company's product portfolio covers wide spectrum of materials for endodontics, prosthodontics, orthodontics, periodontics, restorative dentistry, aesthetic dentistry and laboratory consumables.
86GF Score
Get the complete analysis for BOM:543363
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543363 has been successfully added to your 
